Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5197716
Max Phase: Preclinical
Molecular Formula: C26H33N3O2
Molecular Weight: 419.57
Associated Items:
ID: ALA5197716
Max Phase: Preclinical
Molecular Formula: C26H33N3O2
Molecular Weight: 419.57
Associated Items:
Canonical SMILES: Cc1ccc2c(c1)nc(Cc1ccccc1)n2CC1CCN(C(=O)OC(C)(C)C)CC1
Standard InChI: InChI=1S/C26H33N3O2/c1-19-10-11-23-22(16-19)27-24(17-20-8-6-5-7-9-20)29(23)18-21-12-14-28(15-13-21)25(30)31-26(2,3)4/h5-11,16,21H,12-15,17-18H2,1-4H3
Standard InChI Key: FDLYMKDTXRCWEM-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 419.57 | Molecular Weight (Monoisotopic): 419.2573 | AlogP: 5.58 | #Rotatable Bonds: 4 |
Polar Surface Area: 47.36 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 5.91 | CX LogP: 5.34 | CX LogD: 5.33 |
Aromatic Rings: 3 | Heavy Atoms: 31 | QED Weighted: 0.55 | Np Likeness Score: -1.47 |
1. Bae J, Kang KM, Kim YC.. (2022) Discovery of 5-methyl-1H-benzo[d]imidazole derivatives as novel P2X3 Receptor antagonists., 72 [PMID:35644300] [10.1016/j.bmcl.2022.128820] |
Source(1):